Stock & Company Details
Regeneron Pharmaceuticals, Inc. $REGN
Price:
N/A
N/A
101M
$83B
52 Week High:
N/A
10 Day Average Volume:
N/A
19.63
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
REGN technical indicators
Latest Regeneron Pharmaceuticals, Inc. (REGN) indicator readings as of 2026-08-28.
REGN's 14-day RSI is 55.9, in neutral territory. At $794.19 it is trading 9.0% above its 200-day moving average of $728.69, and above its 50-day average of $716.62. Price sits in the middle of its Bollinger Bands ($755.52 to $849.87). ADX reads 50.0, indicating a trending market.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Finance Bot
Ask your questions
Start by typing a question below.
